uptick

This Is The Only Reason Album Sales Were Up Last Year

Source: http://www.businessinsider.com/this-may-be-the-only-reason-the-music-industry-survived-last-year-2012-1


adele This Is The Only Reason Album Sales Were Up Last Year

For the first time since 2004, album sales are up, and nearly all the credit goes to Adele. Her sophomore album 21 sold nearly 6 million copies, completely dominating the industry and cheering music execs (for once). But given how dependent the industry was on one artist in 2011, is this news really that promising? Here, a guide:

Album sales were up?
Yes, though only slightly. Sales of complete albums in 2011 reached 330.6 million in the U.S., an increase of 1.3 percent over 2010, according to Nielsen. It’s the first uptick in sales since 2004 and Adele deserves much of the credit: Her 21 moved 5.82 million copies — the best one-year sales count since Usher’s Confessions sold 7.98 million in 2004. Her 2009 debut, 19, enjoyed a corresponding bump, selling nearly a million units in 2011 as well.

How significant is this for the music industry?
A one percent increase isn’t exactly something to write home about, says Ben Sisario at at The New York Times.  “Some businesses might call that level of growth flat.” But considering the past decade’s steady downward slide — revenue from recorded music fell 52 percent over the last 10 years — this is a relief. “For the beleaguered music industry, any positive news about sales is cause for celebration.”

How much did Adele dominate?
She sold 3.3 million more albums the year’s second-hi! ghest se ller, Michael Buble’s Christmas, and 3.7 million more than Lady Gaga’s Born This Way. Adele spent 14 weeks atop the Billboard album charts in 2011, says Devon Maloney at Billboard, and 21 is the first album since 2005 to log 30 weeks of 100,000-plus sales. Her song “Rolling in the Deep” was the year’s best-selling single and the most-played song on the radio. Furthermore, 21 is the best-selling digital album of all time. Taken together, her two albums amounted to 2 percent of total record sales, a nearly unprecedented total for one artist. Without her efforts, says Daniel Kreps at SPIN, record sales would actually be down. So while Adele is being hailed as “the savior of music,” says Tyler Coates at Black Book, “the industry is still tanking.”

What about the digital sales?
Digital music sales rose 8.5 percent, says Coates, while sales of complete digital albums rose 20 percent. Though such boosts seem like a good sign for the industry, digital sales offer the lowest profit margin of all music sales. CD sales, which deliver the greatest profit margin, were, unsurprisingly, down six percent.

This post originally appeared at The Week.

Please follow Money Game on Twitter and Facebook.

Join the conversation about this story »

See Also:



 This Is The Only Reason Album Sales Were Up Last Year This Is The Only Reason Album Sales Were Up Last Year


drag2share – drag and drop RSS news items on your email contacts to share (click SEE DEMO)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Sunday, January 8th, 2012 news No Comments

The World’s Largest Blockbuster Drug Just Went Generic — Here Are The Winners And Losers (PFE, WPI, ABC, TEVA, MRK, MYL, CVS, WAG)

Source: http://www.businessinsider.com/the-nations-largest-blockbuster-drug-just-went-generic-2011-11


pfizerap1017 The Worlds Largest Blockbuster Drug Just Went Generic    Here Are The Winners And Losers (PFE, WPI, ABC, TEVA, MRK, MYL, CVS, WAG)

With the expiration of Pfizer’s patent exclusivity on Lipitor, the nation’s top selling drug will go generic and see a market share split that will force manufacturers into a share race.

Lipitor, a cholesterol drug that reduces cholesterol, came to market in 1997 and ultimately peaked with sales of $13 billion. Last year, it contributed $10.7 billion in revenue to Pfizer.

Analysts remain divided over how much market share Pfizer will be able to hold on to. The company is aggressively discounting the drug through a program to entice patients to remain on Lipitor. Over the coming 180 days, Watson Pharmaceuticals and Ranbaxy Laboratories of India will enter the market.

Eight Citi analysts poured over data and see Pfizer retaining 40-50% of market share over the next half year. Delays out of Ranbaxy, which were prompted by U.S. regulatory bans over questionable quality concerns, will aid Pfizer.

But after the 180 days, when another round of pharmaceuticals like Teva and Aurobindo are allowed entry, the cost of Lipitor will drop to “pennies a day,” Citi analyst John Boris writes.

However, most of Lipitor’s decline has already been priced into Pfizer stock over the past year. “We maintain our Pfizer 4Q11E/2012E Lipitor sales/EPS contribution at $930M/$640M,” Boris continues. That represents a Lipitor sales contribution of 14-18% of fourth EPS, before falling to just 2% of earnings in 2012.

The largest to benefit from the change may be drug stores like CVS and Walgreens, which may see an uptick as more patients can afford to take cholesterol medications, even as average drug prices decline.

“In addition, we believe that the drugstores will be able to generate stronger gross profit dollars as the average gross margin for generic drugs is generally 50 to 60%, while the average gross margin for branded drugs is approximately 20%,” Boris says. 

Meanwhile, Pfizer is betting its name on smaller blockbusters in other drug categories to contribute $4 billion in new revenue by 2014 as it re-emerges in a world post-Lipitor.

Please follow Money Game on Twitter and Facebook.

Join the conversation about this story »

See Also:



 The Worlds Largest Blockbuster Drug Just Went Generic    Here Are The Winners And Losers (PFE, WPI, ABC, TEVA, MRK, MYL, CVS, WAG) The Worlds Largest Blockbuster Drug Just Went Generic    Here Are The Winners And Losers (PFE, WPI, ABC, TEVA, MRK, MYL, CVS, WAG)


drag2share – drag and drop RSS news items on your email contacts to share (click SEE DEMO)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Wednesday, November 30th, 2011 news No Comments

Appcelerator developers warm to Windows Phone, give BlackBerry the cold shoulder

Source: http://www.engadget.com/2011/11/15/appcelerator-developers-warm-to-windows-phone-give-blackberry-t/

appcelerator idc 1114 Appcelerator developers warm to Windows Phone, give BlackBerry the cold shoulder

As the year winds to a close, it seems that developer sentiments have shifted since we last checked in with Appcelerator and its opinionated community of coders. In a survey performed in conjunction with IDC, the results suggest a steady interest to develop for smartphones and tablets of the iOS and Android variety, but also reveal a punctuated surge in enthusiasm for Windows Phone. The platform experienced an eight percent uptick since last quarter, with developers citing Nokia’s involvement as a primary motivating factor. While Microsoft’s OS still lags significantly behind the front-runners, it has significantly separated itself from other competitors. For instance, interest in BlackBerry smartphones fell by seven percent, to roughly half that of Windows Phone. It should be noted that this survey doesn’t reflect the development community as a whole, but merely of Appcelerator Titanium users — if you’re curious, the product is a cross-platform development environment for mobile apps. While the 2,160 respondents may not perfectly represent reality, we wouldn’t be surprised if they were darn close.

Appcelerator developers warm to Windows Phone, give BlackBerry the cold shoulder originally appeared on Engadget on Tue, 15 Nov 2011 10:47:00 EDT. Please see our terms for use of feeds.

Permalink post label VIA Appcelerator developers warm to Windows Phone, give BlackBerry the cold shoulderSlashGear  |  post label source Appcelerator developers warm to Windows Phone, give BlackBerry the cold shoulderAppcelerator  | Email this | Comments


drag2share – drag and drop RSS news items on your email contacts to share (click SEE DEMO)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Tuesday, November 15th, 2011 news No Comments

like the iPod touch, only bigger (updated)

Source: http://www.engadget.com/2010/03/30/ipads-trailing-costs-like-the-ipod-touch-only-bigger/

premium ipad apps like the iPod touch, only bigger (updated)

Whether or not you think the iPad is in and of itself a worthy purchase, let’s not forget the investment doesn’t end at the retail counter or online shopping cart. Two little newsbits have popped up to serve as a helpful reminder to just that effect. The first comes way of verbiage from the iPad end-user licensing agreement dug up by MacRumors; in a nutshell, it suggests that while iPad OS 4.x updates will be provided gratis, subsequent releases (5.x, 6.x, and so on) could be offered at a premium, à la how iPod touch handles firmware. This is far from a confirmation, but it’s well within Apple’s right to do so. The second bit is derived by The Consumerist by way a supposed leaked app store video. Comparing the prices of iPad-optimized software with the iPhone equivalents showed quite a hefty uptick in consumer cost — e.g., $4.99 Flight Control HD vs. $0.99 Flight Control. The pool of eight apps seen in the video would cost $53 in all to purchase, while the same set for the iPhone is $27. That screen real estate don’t come cheap, y’know — that is, should the prices seen prove legit. At this point we can’t confirm, and more than likely, we won’t know for sure until the eleventh hour.

Update: The BBC has word direct from developers that iPad apps will indeed be costlier than their iPhone / iPod touch brethren. Multiple devs are cited in the Beeb‘s article saying that their 99 cent apps will grow in price to $1.99 and $2.99 price points for the slate device [thanks, Ben].

iPad’s trailing costs: like the iPod touch, only bigger (updated) originally appeared on Engadget on Tue, 30 Mar 2010 21:07:00 EST. Please see our terms for use of feeds.

Permalink   |  post label source like the iPod touch, only bigger (updated)MacRumors, The Consumerist  | Email this | Comments

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Wednesday, March 31st, 2010 news No Comments

Dr. Augustine Fou is Digital Consigliere to marketing executives, advising them on digital strategy and Unified Marketing(tm). Dr Fou has over 17 years of in-the-trenches, hands-on experience, which enables him to provide objective, in-depth assessments of their current marketing programs and recommendations for improving business impact and ROI using digital insights.

Augustine Fou portrait
http://twitter.com/acfou
Send Tips: tips@go-digital.net
Digital Strategy Consulting
Dr. Augustine Fou LinkedIn Bio
Digital Marketing Slideshares
The Grand Unified Theory of Marketing